A Double Blind Observational Study to Validate the SpotitEarly Test for the Detection of Breast Cancer (The PINK Study)

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

The goal of this study is to find out whether a system that uses trained detection dogs and artificial intelligence (AI) can identify breast cancer from a person's breath. Women who are scheduled to have routine breast cancer screening, such as a mammogram, ultrasound, or a biopsy for a possible cancer, will be invited to take part. Participants will be asked to breathe into a surgical mask to collect a breath sample. The mask will be sent to a special laboratory, where trained dogs and an AI-based system will check the sample for signs of breast cancer. The results from the dogs and AI will be compared to the actual results from the medical screening or biopsy to see how accurate the system is at detecting breast cancer.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: t
View:

• Capable of giving informed consent for self, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

• Assigned female at birth.

• 40 years of age and above OR

• Between 18 and 39 years of age (inclusive) and a carrier of germline pathogenic variants associated with high risk for breast cancer: BRCA1, BRCA2, PTEN, TP53, CDH1, or STK11 ATM, CHEK2, BARD1, RAD51D, RAD51C, PALB2, OR

• Between 18 and 39 years of age (inclusive) with a family history of breast or ovarian cancer involving at least one first or two second-degree relatives who were diagnosed with breast or ovarian cancer before the age of 50 years.

• Scheduled for routine annual breast cancer screening (Mammogram, Ultrasound and MRI)

• Capable of giving informed consent for self, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

• Assigned female at birth.

• 40 years of age and above. OR

• Between 18 and 39 years of age (inclusive) and a carrier of germline pathogenic variants associated with high risk for breast cancer: BRCA1, BRCA2, PTEN, TP53, CDH1, or STK11 ATM, CHEK2, BARD1, RAD51D, RAD51C, PTEN , PALB2 OR

• Between 18 and 30 years of age (inclusive) with a family history of breast or ovarian cancer involving at least one first or two second-degree relatives who were diagnosed with breast or ovarian cancer before the age of 35 years.

• BI-RADS® score of 4B.

• Scheduled for breast biopsy.

Locations
United States
New Jersey
Hackensack Meridian Health
RECRUITING
Totowa
Other Locations
Israel
Rambam Health Care Campus
RECRUITING
Haifa
Sheba Medical Center
RECRUITING
Ramat Gan
Assuta Medical Centers
RECRUITING
Tel Aviv
Tel Aviv Sourasky Medical Center
RECRUITING
Tel Aviv
Contact Information
Primary
Udi Bobrovsky
udi@spotitearly.com
+972-54-456-0008
Time Frame
Start Date: 2025-07-22
Estimated Completion Date: 2027-06
Participants
Target number of participants: 1204
Treatments
Target Population Arm
Women scheduled for routine breast cancer screening by mammography/ultrasound/magnetic resonance imaging
Enriched Arm
Women scheduled for breast biopsy with a Breast Imaging and Reporting Data System (BI-RADS®) score of 4B or above
Related Therapeutic Areas
Sponsors
Collaborators: Hackensack Meridian Health
Leads: SpotitEarly

This content was sourced from clinicaltrials.gov